

**■ CLINICS 2010;65(8):815**

**Replace** Surya Kumar Dubey

**For** Surya Kumar Dube

**■ CLINICS 2013;68(5):686–93**

Fang Peng is the corresponding author

**■ CLINICS 2013;68(6):834–9**

**Page 834 (Abstract)**

**Replace** OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1% prednisolone (Zypred<sup>®</sup>) *versus* the individual components used separately (Zypred<sup>®</sup> and Predfort<sup>®</sup>) for infection prophylaxis and inflammation control after cataract surgery with intraocular lens implantation.

**For** OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1% prednisolone (Zypred<sup>®</sup>) *versus* the individual components used separately (Zymar<sup>®</sup> and Predfort<sup>®</sup>) for infection prophylaxis and inflammation control after cataract surgery with intraocular lens implantation.

**Page 835**

**Replace** The aim of this study was to compare the inflammation control and infection prophylaxis after cataract surgery provided by a fixed combination of gatifloxacin 0.3% and prednisolone acetate 1% (Zypred<sup>®</sup>, Allergan<sup>®</sup>) *versus* the individual components (Zypred<sup>®</sup> and Predfort<sup>®</sup>).

**For** The aim of this study was to compare the inflammation control and infection prophylaxis after cataract surgery provided by a fixed combination of gatifloxacin 0.3% and prednisolone acetate 1% (Zypred<sup>®</sup>, Allergan<sup>®</sup>) *versus* the individual components (Zymar<sup>®</sup> and Predfort<sup>®</sup>).

---

**Copyright** © 2013 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

**DOI:** 10.6061/clinics/2013(08)19